Biomerica, Inc. (NASDAQ:BMRA) – Equities researchers at B. Riley raised their Q1 2020 earnings per share estimates for Biomerica in a note issued to investors on Tuesday, September 10th, according to Zacks Investment Research. B. Riley analyst A. D’silva now anticipates that the company will earn ($0.06) per share for the quarter, up from their previous forecast of ($0.08). B. Riley currently has a “Buy” rating and a $6.00 target price on the stock. B. Riley also issued estimates for Biomerica’s Q2 2020 earnings at ($0.08) EPS, Q3 2020 earnings at ($0.06) EPS, FY2020 earnings at ($0.27) EPS and FY2022 earnings at $0.75 EPS.
Shares of NASDAQ:BMRA opened at $3.15 on Friday. Biomerica has a 1-year low of $1.60 and a 1-year high of $3.78. The firm’s 50 day simple moving average is $3.13 and its two-hundred day simple moving average is $2.69.
Biomerica (NASDAQ:BMRA) last issued its quarterly earnings results on Friday, August 30th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). Biomerica had a negative net margin of 46.01% and a negative return on equity of 58.31%. The business had revenue of $1.17 million for the quarter, compared to the consensus estimate of $1.36 million.
A hedge fund recently bought a new stake in Biomerica stock. Susquehanna International Group LLP bought a new position in Biomerica, Inc. (NASDAQ:BMRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 17,688 shares of the company’s stock, valued at approximately $46,000. Susquehanna International Group LLP owned approximately 0.18% of Biomerica as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.24% of the company’s stock.
About Biomerica
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.